ARVN
Arvinas, Inc.
There isn't enough reported data to score ARVN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ARVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARVN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARVN PE Valuation
ARVN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ARVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARVN's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ARVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.10 | +$0.71 |
| Q2 2026 | $0.24 | +$1.25 |
| Q1 2026 | -$3.18 | -$2.52 |
| Q4 2025 | -$1.14 | +$1.63 |
| Q3 2025 | -$0.81 | +$3.86 |
| Q2 2025 | -$1.01 | +$4.16 |
| Q1 2025 | -$0.66 | +$5.27 |
| Q4 2024 | -$2.77 | +$3.73 |
ARVN is still losing money, but far less than before: $0.10 per share over the past year, against $6.50 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ARVN on earnings quality, reporting a profit while its opponent remains loss making.
ARVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $500K | -99% |
| Q2 2026 | $249.7M | +1015% |
| Q1 2026 | $15.6M | -92% |
| Q4 2025 | $9.5M | -84% |
| Q3 2025 | $41.9M | -59% |
| Q2 2025 | $22.4M | -71% |
| Q1 2025 | $188.8M | +646% |
| Q3 2024 | $102.4M | +196% |
ARVN's revenue is shrinking: $500,000 last quarter, down 99% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11820% | -11716 points |
| Q2 2026 | 66% | +385 points |
| Q1 2026 | -409% | -447 points |
| Q4 2025 | -785% | -687 points |
| Q3 2025 | -105% | -46 points |
| Q2 2025 | -319% | -256 points |
| Q1 2025 | 38% | +367 points |
| Q4 2024 | -98% | N/A |
ARVN's operating margin was −11820% last quarter, down 11715 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ARVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ARVN on profitability, with a higher operating margin.
ARVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.2M | +$49M |
| Q2 2026 | -$48.5M | +$48.1M |
| Q1 2026 | -$70.5M | +$18.8M |
| Q4 2025 | -$30.6M | +$53.8M |
| Q3 2025 | -$59.2M | +$69.5M |
| Q2 2025 | -$96.6M | -295% |
| Q1 2025 | -$89.3M | +$8.3M |
| Q4 2024 | -$84.4M | -$1.2M |
ARVN has burned cash in almost every quarter: −$160M over the past year, against −$330M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ARVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -300K shares |
| 1 year | -11% | -7.8M shares |
| 3 years | +21% | +11.3M shares |
| 5 years | +31% | +15.6M shares |
| Available history | +75% | +28.1M shares |
ARVN has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $74.1M |
| Q4 2023 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ARVN Net Leverage
ARVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ARVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 18.1 | Oversold |
ARVN's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ARVN PE vs Healthcare Sector
| Metric | ARVN | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 27% above |
ARVN has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ARVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.26 | 5.4% below |
| 20 week MA | $8.06 | 15% below |
| 50 week MA | $9.82 | 30% below |
| 100 week MA | $10.2 | 33% below |
| 200 week MA | $19.7 | 65% below |
ARVN is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ARVN on trend strength, trading above more of its moving averages.
ARVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.8 | $82.2 | +97% |
| 2021 | $82.2 | $81.3 | -1.2% |
| 2022 | $81.3 | $32.7 | -60% |
| 2023 | $32.7 | $41.2 | +26% |
| 2024 | $41.2 | $19.0 | -54% |
| 2025 | $19.0 | $12.2 | -36% |
| 2026 YTD | $12.2 | $6.87 | -44% |
ARVN has finished lower in four of the last six years. It's down 44% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ARVN on returns for 2026, with the stronger performance.